Interleukin-1/6 Blockade for the Treatment of Severe Steroid-Refractory BNT162b2 Vaccine-Induced Adult-Onset Still’s Disease
  • Benjamin Hugues
    Service de Médecine Interne, Hôpital Foch, Suresnes, France
  • Hakim Ben Amer
    Service de Cardiologie, Hôpital Foch, Suresnes, France
  • Floriane Bril
    Service de Cardiologie, Hôpital Foch, Suresnes, France
  • Matthieu Groh
    Service de Médecine Interne, Hôpital Foch, Suresnes, France
  • Florent Huang
    Service de Cardiologie, Hôpital Foch, Suresnes, France


Adult-onset Still’s disease, myocarditis, COVID-19, vaccines, biological therapies


Introduction: Several immune-mediated side effects have been reported with COVID-19 vaccines, including myocarditis.

Case description: A 27-year-old woman with a past medical history of mild COVID-19, developed adult-onset Still’s disease (AOSD) with salmon-pink flagellate erythema, polyarthritis, a sore throat, myocarditis and haemophagocytic lymphohistiocytosis after receiving two doses of the BNT162b2 vaccine (Pfizer®, BioNTech®). Despite the initial efficacy of high-dose pulses of methylprednisolone, inflammatory markers rose as soon as de-escalation of corticosteroids was attempted, warranting initiation of biologics targeting the interleukin (IL)-1/6 axis, which allowed sustained remission of the disease despite withdrawal of corticosteroids.

Discussion: To our knowledge, this is the first case of AOSD with both haemophagocytic lymphohistiocytosis and cardiac magnetic resonance imaging-proven myocarditis triggered by COVID-19 vaccination, successfully treated with steroids and biologics targeting the IL-1/IL-6 axis. The pathophysiological process by which COVID-19 vaccination can lead to AOSD is still unknown, although it has been reported that the spike protein may act as a pathogen-associated molecular pattern and thus induce an overproduction of pro-inflammatory cytokines of the innate immune system (e.g., IL-1, IL-6 or IL-18).

Conclusion: Targeting the IL-1/6 axis is effective for the treatment of severe steroid-refractory BNT162b2 vaccine-induced adult-onset Still’s disease. At a population level, the favourable benefit/risk ratio of COVID-19 vaccination remains indisputable.



  • Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med 2021 16;385(12):1078–1090.
  • Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol 2014;66(9):2613–2620.
  • Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol 1992;19(3):424–430.
  • Fautrel B, Zing E, Golmard JL, Le Moel G, Bissery A, Rioux C, et al. Proposal for a new set of classification criteria for adult-onset still disease. Medicine (Baltimore) 2002;81(3):194–200.
  • Feist E, Mitrovic S, Fautrel B. Mechanisms, biomarkers and targets for adult-onset Still’s disease. Nat Rev Rheumatol 2018;14(10):603–618.
  • Leone F, Cerasuolo PG, Bosello SL, Verardi L, Fiori E, Cocciolillo F, et al. Adult-onset Still’s disease following COVID-19 vaccination. Lancet Rheumatol 2021;3(10):e678–680.
  • Magliulo D, Narayan S, Ue F, Boulougoura A, Badlissi F. Adult-onset Still’s disease after mRNA COVID-19 vaccine. Lancet Rheumatol 2021;3(10):e680–682.
  • Muench F, Krusche M, Sander LE, Rose T, Burmester GR, Schneider U. Macrophage activation syndrome in a patient with adult-onset Still’s disease following first COVID-19 vaccination with BNT162b2. BMC Rheumatol 2021;5(1):60.
  • Jeon YH, Lim DH, Choi SW, Choi SJ. A flare of Still’s disease following COVID-19 vaccination in a 34-year-old patient. Rheumatol Int 2022;42(4):743–748.
  • Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov 2018;17(4):261–279.
  • Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395(10229):1033–1034.
  • Views: 632
    HTML downloads: 96
    PDF downloads: 490

    Published: 2022-08-29
    Issue: 2022: Vol 9 No 8 (view)

    How to cite:
    Hugues B, Ben Amer H, Bril F, Groh M, Huang F. Interleukin-1/6 Blockade for the Treatment of Severe Steroid-Refractory BNT162b2 Vaccine-Induced Adult-Onset Still’s Disease. EJCRIM 2022;9 doi:10.12890/2022_003469.